Go Pro
NASDAQ:FTRE

Fortrea Q2 2026 Earnings Report

Fortrea logo
$17.76 -0.16 (-0.89%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$17.77 +0.01 (+0.08%)
As of 07/17/2026 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fortrea EPS Results

Actual EPS
N/A
Consensus EPS
$0.18
Beat/Miss
N/A
One Year Ago EPS
N/A

Fortrea Revenue Results

Actual Revenue
N/A
Expected Revenue
$647.53 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fortrea Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Wednesday, July 29, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Fortrea Earnings Headlines

Fortrea (NASDAQ:FTRE) Upgraded by Wall Street Zen to Buy Rating
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance estimates it could unlock $400 trillion - but analyst Jeff Brown, who was consulted by Congressional offices on the legislation, believes the real figure could reach $2.6 quadrillion. Brown says this shift will pour onto a new type of investment exchange - and he's showing investors how to position themselves starting with just $100.tc pixel
See More Fortrea Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fortrea? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fortrea and other key companies, straight to your email.

About Fortrea

Fortrea (NASDAQ:FTRE), Inc. is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services. Its small-molecule capabilities include custom synthesis, active pharmaceutical ingredient (API) production, and high-potency manufacturing. On the biologics side, the company offers cell line development, microbial and mammalian cell culture, purification, viral vector production, and fill-finish operations. Complementing these laboratory and production capacities, Fortrea delivers quality assurance, regulatory support, and supply chain management to help clients navigate stringent global regulatory environments.

With its headquarters in Horsham, Pennsylvania, Fortrea operates a network of facilities across North America, Europe, and Asia, serving a diverse international client base. These strategically located sites enable the company to provide flexible manufacturing scales—from gram-scale clinical batches to multi-metric-ton commercial volumes—while ensuring continuity of supply and localized regulatory compliance. Fortrea’s global footprint supports time-sensitive project needs and offers clients access to specialized technologies and expertise in multiple regions.

Led by Chief Executive Officer James Mullen, Fortrea’s leadership team draws on decades of experience in pharmaceutical development and manufacturing. The company’s executive management combines technical know-how with a customer-focused approach, aiming to foster long-term partnerships and drive innovation. As a newly independent entity, Fortrea continues to invest in capacity expansions and technology upgrades to meet the evolving demands of the life sciences industry.

View Fortrea Profile